Friday, September 2, 2016
Jaguar Animal Health, Inc. develops and commercializes first-in-class gastrointestinal products for companion and production animals. Canalevia is the company's prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs.
SpeculatingStocks.com Stock Pick
► Jaguar Animal Health, Inc. (JAGX)
Stock Price: $1.43
JAGX just announced yesterday, September 1st, that their Neonorm Calf drug trial for cows met its topline goals. This is a great sign considering that the company also expressed that they are in the negotiation process for a potential exclusive distribution relationship for Neonorm in the Chinese market.
The Neonorm Calf product is non-prescription and designed to help dairies and calf farms proactively retain fluid in calveshelping the animals avoid debilitating, dangerous levels of dehydration.
JAGX currently trades at market cap of 15.90 million with a 52-week high of $4.70. The company had revenue of $258k in 2015, but the potential Chinese market deal could be a major catalyst to adoption of their Neonorm product.
JAGX has $3.87 million in cash on the balance sheet as of 6/30/2016. JAGX is a highly speculative play, but it traded 5.92 million shares on Thursday and is starting to get eyes on it and with a potential catalyst ahead, this could be a strong short-term play.
Speculative Score: 10
1 Being the Least Speculative and Most Confident
10 Being the Most Speculative and Possibly the Most Risky